Key Dates

Related Announcements

PAR-20-111 - Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to clarify the Application Types Allowed for PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional). The Activity Code section (Part 1. Overview Information) has been modified to remove the following text "U44Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II". This text is being removed to be consistent with Section II. Award Information stating that only New (Fast-Track) applications will be accepted in response to this Funding Opportunity Announcement (FOA). This change will be effective for the August 11, 2020 receipt date and subsequent due dates.Changes to the FOA are shown below.

Currently Reads:

Part 1. Overview Information

Modified to Read:

Part 1. Overview Information

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Charles Cywin, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email:charles.cywin@nih.gov